1
|
Sun DQ, Wu SJ, Liu WY, Lu QD, Zhu GQ, Shi KQ, Braddock M, Song D, Zheng MH. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets 2015; 20:375-87. [PMID: 26419119 DOI: 10.1517/14728222.2016.1096930] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is a major, worldwide public health problem. NAFLD is recognized as a major cause of liver-related morbidity and mortality. However, physicians are currently limited by available treatment options. Recently, numerous studies have reported a correlation between serum uric acid (SUA) and NAFLD with numerous clinical and experimental studies demonstrating a significant correlation. This review will focus on the role of SUA in the development of NAFLD and its potential role as a new target for therapeutic intervention. AREAS COVERED This review discusses SUA as a significant independent factor in the development of NAFLD. Moreover, we introduce the causal relationship between SUA, metabolic syndrome, and NAFLD. We discuss two major theories of insulin resistance and inflammasomes as potential explanations of the mechanistic link between SUA and NAFLD. In addition, we review current and emerging therapeutic medications to control appropriate SUA levels. EXPERT OPINION There is an urgent need to develop novel, safe and effective therapies for the growing NAFLD epidemic. Reduction of SUA may be a promising potential treatment for patients with NAFLD. Clinical studies are required to determine the therapeutic effect of attenuation of hyperuricemia in humans with NAFLD.
Collapse
Affiliation(s)
- Dan-Qin Sun
- a 1 Nanjing Medical University, Affiliated Wuxi Second Hospital, Department of Nephrology , Wuxi 214002, China
| | - Sheng-Jie Wu
- b 2 The First Affiliated Hospital of Wenzhou Medical University, the Heart Center, Department of Cardiovascular Medicine , Wenzhou 325000, China
| | - Wen-Yue Liu
- c 3 The First Affiliated Hospital of Wenzhou Medical University, Department of Endocrinology , Wenzhou 325000, China
| | - Qian-Di Lu
- a 1 Nanjing Medical University, Affiliated Wuxi Second Hospital, Department of Nephrology , Wuxi 214002, China
| | - Gui-Qi Zhu
- d 4 The First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases , Wenzhou 325000, China and .,e 5 Wenzhou Medical University, School of the First Clinical Medical Sciences , Wenzhou 325000, China
| | - Ke-Qing Shi
- d 4 The First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases , Wenzhou 325000, China and .,f 6 Wenzhou Medical University, Institute of Hepatology , Wenzhou 325000, China
| | - Martin Braddock
- g 7 Global Medicines Development, AstraZeneca R&D , Alderley Park, UK
| | - Dan Song
- a 1 Nanjing Medical University, Affiliated Wuxi Second Hospital, Department of Nephrology , Wuxi 214002, China
| | - Ming-Hua Zheng
- d 4 The First Affiliated Hospital of Wenzhou Medical University, Liver Research Center, Department of Infection and Liver Diseases , Wenzhou 325000, China and .,f 6 Wenzhou Medical University, Institute of Hepatology , Wenzhou 325000, China
| |
Collapse
|